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INTRODUCTION
Nonfermentative Gram negative bacilli  (NFGNB) are  a  group of  aerobic,  non 
spore forming organisms that either do not use carbohydrates as a source of energy or 
degrade them through metabolic pathways other than fermentation.57, 106, 107
These bacteria are ubiquitous in nature particularly in soil and water. Although 
frequently considered as contaminants, most of the nonfermenting gram negative bacilli 
have emerged as important nosocomial  pathogens causing opportunistic infections in 
immmunocompromised  hosts.  Humidifiers,  ventilator  machines,  dialysate  fluids  and 
catheter  devices  in  the  hospital  environment  have  provided  opportunities  for  these 
organisms to establish infection. 74, 90
Non-fermenting  Gram  negative  bacilli  cause  variety  of  infections  including 
urinary  tract  infections,  wound  infections,  septicemia,  pneumonia,  osteomyelitis, 
meningitis  etc.  They  are  being  recovered  with  increasing  frequency  from  clinical 
specimens.  Chronic  infection,  longer  duration  of   hospitalization  and  prolonged 
antibiotic therapy  are the predisposing factors for infection with nonfermenters. This 
group  includes  organisms  from  diverse  genera  like  Pseudomonas, Acinetobacter,  
Stenotrophomonas,  Burkholderia,  Alcaligenes,  Weeksella  etc,  with  Pseudomonas 
aeruginosa being the predominant species recovered  from clinical specimens. 49, 90,107
Nonfermenters generally require more effort for their identification as they have 
metabolic  pathways  requiring  the  use  of  special  biochemical  tests.  In  most  of  the 
laboratories they are not identified upto species level as it is routinely not possible. For 
this reason, reports of diseases due to these organisms are rare. The rise in incidence of 
these infections necessitates their characterization upto species level.38,39
Members  of  nonfermenting  gram negative  bacteria  show resistance  to  a  wide 
range of commonly used antibiotics leading to serious infections like sepsis. Multidrug 
resistance exhibited by them especially the organisms of great current importance like 
Acinetobacter baumanni  and Ps.aeruginosa pose a major clinical problem in treating 
infections caused by them. Therefore early identification and institution of appropriate 
treatment is necessary to reduce the morbidity and mortality due to these organisms in 
hospitalized patients.47
Nonfermenters often use several different mechanisms of resistance. One among 
them is production of Extended Spectrum of BetaLactamases (ESBL). ESBL are a group 
of betalactamases which share the ability to hydrolyse third generation cephalosporins 
and are inhibited by clavulanic acid. They are plasmid coded.23
Production of carbapenamases is the other mechanism of resistance to antibiotics 
by the nonfermenters. These enzymes have high hydrolytic activity against penicillins, 
cephalosporins, and carbapenams. Resistance to carbapenams in nonfermenters can be 
intrinsic or acquired. Intrinsic resistance is seen in S.maltophilia while acquired Class B 
metallobetalactamases (MBL) and class D serine carbapenamases are frequently found 
in  Ps.aeruginosa and  Acinetobacter  respectively.  These  acquired  MBL genes  (IMP, 
VIM,  SPM, GIM types)  are  usually  clustered  with  other  resistance  determinants  on 
mobile  DNA elements  and their  presence  is  virtually  constant  marker  for  multidrug 
resistance. They have the potential to spread rapidly to other species causing nosocomial 
outbreaks  of  carbapenam  resistance.  Regular  monitoring  and  documentation  of 
carbapenam resistance is therefore crucial in developing strategies to control infections 
due to these bacteria.40,48,69, 89, 92,102,109
Within hospitals,  the unnecessary use or  overuse of antibiotics encourages the 
selection and proliferation of resistant strains of bacteria. It is not possible to completely 
eliminate this evolutionary phenomenon, but it can be modified by prudent antibiotic 
use.  This  requires  the  inclusion  of  an  antibiotic  policy  in  the  infection  control 
programme.
The present study was therefore undertaken to identify the nonfermenters from 
various clinical specimens, to analyse the risk factors associated with their infections, to 
determine the multidrug resistance and to guide initial empiric therapy for infections 
caused by them.
AIMS AND OBJECTIVES
 To isolate and speciate the nonfermenters from various clinical specimens.
 To study the sensitivity patterns of the isolates with common antimicrobials.
 To detect the incidence of multidrug resistance among nonfermenters.
 To detect the production of extended spectrum of betalactamases.
 To detect  the acquired resistance to carbapenam antibiotics and production of 
acquired metallobetalactamases.(MBL)
 To identify the genes responsible for acquired MBL production
 To formulate antibiotic therapy for the infections caused by nonfermenters.
REVIEW OF LITERATURE
Nonfermenting Gram Negative Bacilli  (NFGNB) are a group of taxonomically 
diverse organisms growing significantly under aerobic conditions.  They all  share the 
common phenotypic feature of failing to acidify the butt of Triple sugar iron agar (TSI) 
or Kligler iron agar (KIA) agar or of oxidative-fermentative (OF) media.74
Aerobic  nonfermenters  are  cosmopolitan  in  their  distribution  inhabiting  soil, 
water, plants and animals. Their medical importance derives principally from their being 
opportunistic  pathogens  and  clinical  diseases  they  cause  are  nosocomial  in  origin. 
Approximately 15% of all  gram negative clinical isolates are nonglucose fermenting 
gram negative rods. Of these, more than 2/3rds are Pseudomonas aeruginosa.49, 92
Large group of these nonfermenters have undergone confusing taxonomic changes 
for  many  years.  New  definitions  of  species  and  genera  using  modern  genotyping 
analysis,  together  with  reliable  identification  methods  have  resulted  in  a  better 
knowledge of these bacteria and a significantly increased awareness of their pathogenic 
role in hospitals and in rare cases of community acquired infections.49, 57
The major genera of nonfermenting Gram negative bacilli have been classified 
into atleast  15 families inaddition to a number of clinically important  nonfermenters 
with uncertain taxonomic positions. Medically important nonfermenters can be grouped 
on the basis of presence / absence of motility and the type of flagella present in strains 
that are motile.57
MOTILE WITH POLAR FLAGELLA
FamilyPseudomonadaceae(rRNA groupI) 
Genus Pseudomonas 
Family  Burkholderiaceae (rRNA  group 
II)
Genus Burkholderia
Genus Cupriavidus
Genus Lautropia
Genus Pandoraea
Genus Ralstonia 
Family Comamonadaceae
 (rRNA group III)
Genus Comamonas
Genus Acidovorax
Genus Delftia 
Family Caulobacteraceae
(rRNA Group IV)
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Family Xanthomonadaceae
(rRNA Group V)
Genus Stenotrophomonas 
Family Sphingomonadaceae
Genus Sphingomonas 
Family Oceanospirillaceae
Genus Balneatrix 
Family Alteromonadaceae
Genus Alishewanella
Genus Shewanella
Family Oxalobacteraceae 
Genus Herbaspirillum
Genus Massilia 
Family Methylobacteriaceae
Genus Methylobacterium
Genus Roseomonas 
Organisms Whose Taxonomlc 
Position Is Uncertain
CDC Groups Ic, O-l, O-2, O-3, Vb-3
MOTILE WITH PERITRICHOUS 
FLAGELLA
NONMOTILE, OXIDASE 
NEGATIVE
Family Alcaligenaceae 
Genus Achromobacter 
Genus Alcaligenes
Genus  Bordetella  (B.  avium, B.  .  hinzii,  B.  
bronchiseptica, B. trematumatum)
Genus Kerstersia
Genus Oligella (O. ureolytica)
 Family Rhizobiaceae
Genus Rhizobium 
Family Brucellaceae
Genus Ochrobactrum 
Family Halomonadaceae
Genus Halomonas
Family Moraxellaceae
Genus Acinetobacter 
Family Alcaligenaceae
Genus  Bordetella  (B.  pertussis,  B.  
parapertussis, B. trematum) 
Organisms Whose Taxonomlc 
Position Is Uncertain
CDC group NO-1
CDC group EO-5
NONMOTILE ,OXIDASE POSITIVE
Family Flavobacteriaceae
Genus Flavobacterium
Genus Bergeyella
Genus Chryseobacterium
Genus Empedobacter
Genus Myroides
Genus Weeksella
Family Sphingobacteriaceae
Genus Sphingobacterium
Genus Pedobacter 
Family Moraxellaceae
Genus Moraxella
Genus Psychrobacter 
Family Neisseriaceae
Genus Neisseria 
Family Alcaligenaceae
Genus Oligella (O. urethralis) 
Family Rhodobacteraceae
Genus Paracoccus (EO-2) 
Organisms Whose Taxonomic Position Is 
Uncertain
CDC groups EO-3, EO-4, EF-4b 
CDC groups lIc, IIe, Ilg, IIh. IIi,
Gilardi rod group 1
Among these  the  most  commonly  isolated  organisms in  clinical  specimens  in 
descending order of importance are:
1. Pseudomonas aeruginosa
2. Acinetobacter baumanii
3. Stenotrophomonas maltophilia
4. Burkholderia cepacia
with species of  Flavobactericeae family  and  Alcaligenes groups recently been 
recognized as potential pathogens 49, 90
RISK  FACTORS  FOR  THE  DISEASES  CAUSED  BY  NONFERMENTING 
GRAM NEGATIVE BACILLI 4, 92, 90, 75
1. Immunosuppression  –  Diabetes  mellitus,  malignancy,  steroids  /  antibiotic 
treatment and transplantation.
2. Trauma – gunshot, knife wounds, punctures, surgical wounds and burns.
3. Foreign body implantation – catheters(urinary / blood stream), Prosthetic devices 
– joints, valves, corneal implants, contact lenses.
4. Infused fluids – dialysate, saline irrigations.
5. Prolonged hospitalization especially in Intensive Care Units.( ICUs )
PSEUDOMONAS AERUGINOSA
Ps.aeruginosa is the most common organism isolated among the nonfermenters 
from the clinical specimens, more often than all other Pseudomonas species especially 
in teaching hospitals with more than 500 beds.96, 82 They are ubiquitous organisms widely 
distributed in nature. They have emerged as a major hospital pathogens because of their 
ability to grow in a variety of environments with minimal nutritional requirements.38 
Intensive care units, Immunosuppressants, invasive procedures and antibiotic usage have 
provided opportunities  for  emergence,  persistence  and  transmission  of  Pseudomonas 
between patients, from patients to staff and to inanimate reservoirs.  105 Many carriage 
sites  like  respiratory  tract,  genitourinary  tract  and  skin  serve  as  source  of 
dissemination.67 
The virulence is multifactorial  including loss of host  defence mechanisms like 
immunosuppression, loss of mucosal barrier, cellular factors, toxins elaborated by  Ps 
aeruginosa like endotoxins, exotoxin A, enzymes like elastases, alkaline protease and 
hemolysins are responsible for many of the systemic manifestations of  Pseudomonas 
disease.67,96  .In addition, the colonies of the organism form biofilms within which they 
are protected from host defenses and antimicrobial agents and communicate with each 
other through complex system of cell to cell signaling called Quorum sensing. 15, 96 .The 
production of alginate and epithelial cell tropism in cystic fibrosis is associated with 
poor prognosis and high mortality.75
In  the  National  Nosocomial  Infection  Surveillance  (NNIS)  survey  from  the 
Centres for Disease Control and Prevention (CDC), it is the fourth most common cause 
of nosocomial infection and leading cause of hospital acquired infections..90   It is the 
most  common  cause  of  wound  infection  caused  by  gram negative  bacteria  with  an 
isolation rate  of  upto 62%.96 Urinary  tract  infections  caused by these  organisms are 
mostly hospital acquired and isolations range from 12%-30%.92 It causes life threatening 
bacteremia especially in intensive care settings at a rate of  10%. Ps aeruginosa is the 
leading cause of pneumonia in ICU patients with a mortality of 80 -100% 49
Other infections caused by Ps aeruginosa are osteochondritis, chronic suppurative 
otitis  media,  external  ear  infections,  meningitis  following  trauma  and  surgery, 
endochondritis and peritonitis 74, 110
IDENTIFICATION 57
Ps aeruginosa produces large flat colonies with spreading and serrated edges with 
a  metallic  sheen.  Various  diffusible  pigments  are  produced  like  pyoverdin  and 
pyocyanin. It is betahemolytic on blood agar It produces nonlactose fermenting colonies 
on MacConkey agar. They are motile organisms. It is oxidase positive, catalase positive , 
indole negative, citrate and urease variable. It oxidizes glucose in OF media, reduces 
nitrates  to  nitrites,  arginine  is  decarboxylated,  acetamide  positive,  ONPG  negative, 
sensitive to Polymixin B and grows at 42O.C which differentiates it from Pseudomonas 
fluorescens and Pseudomonas putida.
ANTIBIOTIC SENSITIVITY
They are sensitive to semisynthetic penicillins like Piperacillin/Ticaricillin, third 
generation  cephalosporins  (ceftazidime),  carbapenams  (imipenam  and  meropenam), 
monobactams, aminoglycosides and fluroquinolones.49, 75
It  is intrinsically resistant  to ampicillin,  amoxycillin and amoxicillin-clavulanic 
acid due to an inducible chromosomal AmpC beta lactamase.47, 85
Multiple resistance in these organisms is frequent, leading to the development of 
multidrug  and  pandrug  resistant  Ps.aeruginosa strains  caused  by  mutations  &  or 
production  of  betalactamases  ranging  from  extended  spectrum of  betalactamases  to 
metallobetalactamases.31,34,74
ACINETOBACTER BAUMANII
Acinetobacter are  strictly  aerobic,  gram  negative  coccobacillary  rods,  widely 
distributed in nature and hospital environments 8 45, 74 They are second most commonly 
isolated nonfermenters in human specimens next to  Pseudomonas aeruginosa with a 
prevalence of 10% of all gram negative isolates.74,90 They are generally considered as 
nonpathogic  but  cause  serious  infections  in  debilitated  patients.  The  species  most 
frequently  isolated is  A.baumanii  It  is  most  often  responsible  for  hospital  acquired 
infections.74, 87 They are the most common gram-negative organisms to be isolated from 
the hands of medical personnel.90
A study  conducted  by  CDC has  reported  A.baumanii to  be  the  cause  of  1% 
nosocomial blood stream infections(CDC) A mortality of 17- 46% is associated with 
nosocomial bacteremia by these organisms. 28.
Analysis  of  data  from  the  NNIS  system  showed  that  the  proportion  of  ICU 
pneumonia episodes range from 4% -7%.47 
These organisms have high rate of colonization of the trachea. Respiratory tract is 
the  most  common  site  for  A.baumanii infections  in  ICU  with  a  mortality  rate 
approaching 70%. 67. 
Traumatic  wounds,  burns  and  postoperative  surgical  site  infections  are  also 
common with multidrug resistant strains being observed. 5
Several  reviews  have  described  these  organisms  in  2-6%  of  nosocomially 
acquired urinary tract infections. 5, 7,8,49
IDENTIFICATION57
Colonies are translucent to opaque, convex  and entire with a diameter between 
0.5 and 2mm. It produces nonlactose fermenting colonies on MacConkey agar with a 
pinkish  tint.  It  is  oxidase  negative,  nonmotile,  catalase  positive,  citrate  positive  and 
urease negative. It oxidizes glucose and 10% lactose and dextrose in OF media. It does 
not  reduce  nitrates  to  nitrites.  It  deaminates  arginine,  acetamide  negative,  ONPG 
negative and grows at 44oC.
ANTIBIOTIC SUSCEPTIBILITY 5,57, 47,87
They are universally resistant to penicillin, ampicillin and chloramphenicol. They 
show variable susceptibility  to second and third generation cephalosporins.  Recently 
extended  spectrum  of  betalactamases  and  carbapenamase  resistance  is  reported  in 
nosocomial infections.
STENOTROPHOMONAS MALTOPHILIA
Originally classified as Pseudomonas maltophilia, it is an obligate aerobe and an 
ubiquitous organism73,92,104 It is an emerging opportunistic pathogen.73 It is the third most 
common  encountered  nonfermenter  in  clinical  laboratory  next  to  Pseudomonas and 
Acinetobacter.57,92
It is an important nosocomial pathogen associated with substantial morbidity and 
mortality especially in immunosuppressed patients.96 It is one among the most common 
causes of wound infections due to trauma. It is frequently isolated from patients with 
ventilatory support in ICU.74 It is an important pathogen in cystic fibrosis patients..104  It 
produces  proteolytic  enzymes,  deoxyribonucleases,  ribonucleases,  hemolysins, 
hyaluronidase and mucinase etc. which contribute to its severity in immunosuppressed 
patients.49
The rate of infections caused by S.maltophilia is increased in recent years and are 
being isolated from wound infections, bacteremia, pneumonia, urinary tract infections, 
meningitis and peritonitis..74
IDENTIFICATION 57,104
Colonies formed are pale yellow / lavender green with good growth on Blood agar 
and MacConkey agar. It is oxidase negative, motile, catalase positive, indole negative, 
citrate variable, urease negative. It oxidizes glucose and maltose, decarboxylates lysine, 
ONPG positive, with variable nitrate reduction.
ANTIBIOTIC SUSCEPTIBILITY
Therapy for S.maltophilia infections is problematic because of the broad antibiotic 
resistance  that  typifies  this  organism.90  The  most  active  agents  are   trimethoprim-
sulphamethoxazole, colistin and quinolones. Like other nonfermenters it is intrinsically 
resistant  to  many  common antibiotics  like  aminoglycosides,  carbapenams and  many 
betalactam agents. 57,72
BURKHOLDERIA CEPACIA
It is a motile free living phytopathogen identified as both endemic and epidemic 
nosocomial pathogen 104.Its detection rates are low, in the range of 1%-16% of clinical 
samples..90, 96  It belongs to rRNA group Ie. It produces virulence factors like proteases, 
lipases, exopolysaccharides and lipopolysaccharides..8, 1l
A few case reports have described serious infections, including severe pneumonia, 
invasive otitis and sepsis in cystic fibrosis patients49 Diabetes mellitus is a potential risk 
factor for development of infections.by B.cepacia.57 
B.cepacia is  also  an  important  pathogen  among  patients  with  chronic 
granulomatous  disease.80  Like  other  nonfermenters,  it  can  contaminate  disinfectant 
solutions  The major importance of this organism lies in its role as opportunistic agent of 
pneumonia in cystic fibrosis patients seeded in sputum samples.81
The  spectrum  of  infections  by  these  organisms  includes  wound  infections, 
bacteremia, UTI, pneumonia, meningitis, peritonitis, and endocarditis.96
IDENTIFICATION57
Colonies are smooth and glistening, forming non-lactose fermenting colonies on 
MacConkey agar and yellow pigmented colonies on blood agar. It is weakly oxidase 
positive,  catalase  positive,  motile,  oxidizes  all  sugars,  decarboxylates  lysine,  ONPG 
negative, acetamide negative and resistant to Polymixin B. Nitrate reduction is variable.
ANTIMICROBIAL SUSCEPTIBILITY
As with other nonfermenters intrinsic antibiotic resistance typifies B.cepacia and 
greatly complicates treatment. Trimethoprim-sulfamethoxazole has historically been the 
drug of choice. Most active agents are, ceftazidime, meropenam, ciprofloxacin and other 
quinolones.47, 57, 90
ALCALIGENES FECALIS
It belongs to Alcaligenaceae family.104 It exits in soil and water and in the hospital 
environment.  It  is  isolated  from  various  environmental  sources  like  respirators, 
hemodialysis systems, intravenous solutions and disinfectants.  96
They are important causes of hospital acquired infections in patients who have 
severe underlying diseases. It is found in ulcers of diabetics, urinary tract infections, 
blood, sputum, CSF and wound burns.49
IDENTIFICATION 57
Colonies are thin, spreading with irregular edges on MacConkey and a greenish 
discolouration on blood agar.  It  is  catalase  positive,  oxidase  positive,  motile,  citrate 
positive,  urease  negative,  reduces  nitrite  but  not  nitrate,  acetamide  positive,  ONPG 
negative, and sensitive to polymixin B.
ANTIMICROBIAL SENSITIVITY 57
They  are  resistant  to  aminoglycosides,  chloramphenicol,  tetracycline, 
ciprofloxacin, betalactams and carbapenams.
PSEUDOMONAS FLUROSCENS
P.fluroscens is  a  psychrophilic  organism  which  favours  its  presence  in  blood 
products.49. Outbreaks  of  bacteremia,  respiratory  tract  infections  in  cystic  fibrosis 
patients, wound infections, urinary tract infections and rare cases of community acquired 
pneumonia  have  been  reported..104 They  behave  as  opportunistic  pathogens  in 
immunocompromised patients.57
IDENTIFICATION 57
Colonies are large with spreading edges forming nonlactose fermenting colonies 
on  MacConkey  agar  and  hemolytic  colonies  on  blood  agar.  It  is  oxidase  positive, 
catalase positive, motile, oxidizing glucose, deaminating arginine, reducing nitrates to 
nitrites, ONPG negative, acetamide negative, sensitive to polymyxin B and do not grow 
at 42oC
ANTIBIOTIC SUSCEPTIBILITY 47,57
It is sensitive to antipseudomonal penicillins like Piperacillin, betalactam agents 
and carbapenams. It is resistant to penicillins.
WEEKSELLA VIROSA 57
Flavobactericeae comprises  indole  positive  organisms  like  Chyseobacterium,  
Empedobacter, Spingobacterium and Weeksella.49
Weeksella virosa are associated with urinary tract infections.49
IDENTIFICATION57
Weeksella virosa form yellow colonies on blood agar. They are oxidase positive 
and nonmotile, form indole, citrate variable and urease negative, do not oxidizes glucose 
and  maltose.  They  are  nitrate  negative.  Weeksella is  sensitive  to  penicillin  and 
polymyxin B.
ANTIBIOTIC SUSCEPTIBILITY57
They are resistant to aminoglycosides, third generation cephalosporins, Imipenam 
and erythromycin. They are sensitive to ciprofloxacin and betalactamase inhibitors.
MULTIDRUG  RESISTANCE  IN  NONFERMENTING  GRAM  NEGATIVE 
BACILLI
Nonfermenting Gram Negative Bacilli  pose a particular difficulty for healthcare 
community because they represent the problem of multidrug resistance to the maximum 
47 They are resistant to three or more drugs and important members of this group are Ps.  
aeruginosa, A.baumanii., S.maltophilia and B.cepacia 22. They use several mechanism of 
resistance including intrinsic and rapidly acquired resistance. Intrinsic resistance is due 
to relative impermeability of outer membrane proteins compared to that of other gram 
negative  bacteria  (ten  fold  times  lower).  Efflux  system also  contributes  to  intrinsic 
resistance Acquired resisitance is by mutational changes and acquisition of exogenous 
genetic material. Lastly resistance may also develop during therapy turning an initially 
susceptible isolate into a resistant one.75 Ps. aeruginosa exhibits multidrug resistance to 
4  antibiotic  classes  -ceftazidime,  imipenam,  gentamicin,  and  a  fluroquinolone.  The 
increase  in  multidrug  resistant  strains  suggests  that  therapy  with  compounds  like 
polymyxinB or colistin must be considered.47 A report in Germany revealed multidrug 
resistant profiles in Acinetobacter to drugs like cefepime, ciprofloxacin and amikacin 47 
S.maltophilia and B.cepacia are associated with intrinsic drug resistance.40, 92 Multidrug 
antibiotic resitance negatively affects outcomes of the patients.47.
EXTENDED SPECTRUM OF BETALACTAMASES 23, 112, 
ESBL are a group of betalactamases which share the ability to hydrolyse third 
generation cephalosporins and are inhibited by clavulanic acid. They are plasmidcoded. 
Carbapenams are  treatment  of  choice  for  serious  infections  due  to  ESBL producing 
organisms. ESBLs in nonfermenters are Ambler class A. These enzymes are SHV type, 
TEM type, TEM 1 and 2, CTX-M type, OXA- type , PER- type, VEB, BES – types and 
others. Screening tests for ESBL producers are disk diffusion and dilution susceptibility 
testing methods. The phenotypic confirmatory tests for ESBL production are:
1. Cephalosporin / clavulanate combination disks.20
2. Broth microdilution tests 20
3. E tests 20, 22
CARBAPENAMASES AND METALLOBETALACTAMASES82,89, 102, 109
Carbapenamases  are  betalactamases  with  versatile  hydrolytic  capacities.  They 
have  the  ability  to  hydrolyze  penicillins,  cephalosporins,  monobactams,  and 
carbapenams. Bacteria producing these betalactamases may cause serious infections in 
which  the  carbapenamases  activity  renders  many  betalactams  ineffective.  They  are 
members of  molecular  class  A, B,and D betalactamases.  Class A and D have serine 
based hydrolytic mechanisms while class B are metallobetalactamases that contain zinc 
in  the  active  site.  Class  D  carbapenamases  consist  of  OXA  type  betalactamases 
frequently  detected  in  Acinetobacter  baumanii.  The  metallobetalactamases  belong to 
IMP,  VIM,  SPM,  GIM  and  SIM   families  and  have  been  detected  primarily  in 
Pseudomonas aeruginosa. Nonfermenters especially P.aeruginosa and A.baumanii have 
acquired metallobetalactamases through genetic elements ( plasmids / transposons) and 
can be transmitted to other bacteria. These enzymes confer resistance to all carbapenams 
(Imipenams,  Meropenams,  Ertapenams),  all  betalactams,  aminoglycosides  and 
quinolones.  The  dissemination  is  thought  to  be  driven  by  regional  consumption  of 
ESBLs.  S.maltophilia  is  naturally  resistant  to  imipenam and meropenam because  of 
chromosomally mediated carbapenamase production.42
The families  and subgroups of  carbapenamases  known till  now are IMP-1&2, 
VIM-1&2, SPM-1, GIM-1, and SIM-1.
IMP was first discovered in  Ps.aeruginosa in Japan.and this has spread to other 
gram negative bacteria and reports show their detection in  A.baumanii,  Serratia and 
Klebsiella. Currently IMP family members number upto 18 in the published literature.
The second dominant group of acquired MBLs is the VIM type enzymes. It was 
first described in Verona Italy, from Ps aeruginosa isolate. This family currently consists 
of 14 members and seen mostly in Pseudomonas aeruginosa. It has dubious distinction 
of being the most reported metallo-beta-lactamase worldwide. These genes are easily 
transferred on mobile elements among species. While considered by some to be rare, 
reports of their occurrence have increased. 
DETECTION OF CARBAPENAMASES 89
1. Raise in MIC of carbapenams in the range of 8 >128 µgm / ml.
2. Microbiological test with inhibitors:
a. Disc approximation test with EDTA 113
b. Combined disc method: Imipenam with EDTA 62, 63
c. E test strips with Imipenam and Imipenam EDTA combination88
d. Modified Hodge test 62 
Of these tests, studies conducted showed that both combined disc test and E 
test were more sensitive and equally effective for MBL detection.
MOLECULAR TESTS 40, 89, 102, 109
When the presence of a carbapenamase is suspectd, PCR is the fastest way to 
determine which family of betalactamase is present. Ultimately the identification of the 
betalactamase gene requires sequencing of the entire coding region.
MATERIALS & METHODS
STUDY PERIOD
This cross sectional study was conducted from May2008-June 2009
PLACE OF STUDY
Institute of Microbiology, Madras Medical College, Chennai-3.
ETHICAL CONSIDERATION
Ethical clearance was obtained from Institute of Ethical committee, Government 
General Hospital, Madras Medical College, Chennai -3 Informed consent was obtained 
from the patients before enrolment into the study.
STATISTICAL ANALYSIS
All statistical  analyses were carried out  using SPSS for  Windows. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated.  P values were calculated 
using the chi-square test. A P value of < 0.05 was considered significant.
SAMPLE 
A total of 156 nonfermenting bacteria isolated from various clinical specimens 
like pus, urine, blood, bronchoalveolar lavage, endotracheal aspirations, drain tip and 
cerebrospinal  fluids  collected  from  both  outpatients  and  inpatients  of  Government 
General Hospital, Chennai were studied.
SAMPLE PROCESSING
The  samples  were  processed  according  to  standard  procedures  available.  The 
collected samples were subjected to direct Gram stain and all specimens were inoculated 
onto nutrient agar, 5% sheep blood agar and MacConkey’s agar medium. Urine samples 
were inoculated onto Cystine Lactose Electrolyte Deficient agar (CLED).
All  the catalase positive,  oxidase positive and negative,  nonlactose fermenting 
colonies on Mac Conkey agar were provisionally identified by colony morphology and 
pigment production. They were inoculated in Triple sugar iron (TSI) agar slope. The 
colonies which failed to acidify the TSI agar were considered as nonfermenters and 
subjected  to  the  following  tests.(annexure)  Motility,  Indole,  Citrate,  Urease,  Nitrate 
reduction, growth at 42o c and 44oc, Sensitivity to Polymyxin B and following special 
biochemical tests and grouped according to P.C.Schreckenberger scheme57
SPECIAL BIOCHEMICAL TESTS  USED  FOR  IDENTIFICATION  OF NON 
FERMENTERS 
1. HUGH – LEIFSON OXIDATION - FERMENTATION MEDIUM57
Two tubes were required for the test, each inoculated with the unknown organism, using 
a straight needle stabbing the medium three to four times half way to the bottom of the 
tube. One tube of each pair was covered with a 1cm layer of sterile mineral oil (or) 
melted paraffin, leaving the other open to the air. Both tubes were incubated at 350C and 
examined daily for several days.
In case of oxidative metabolism, yellow color appears along the upper one fourth 
of the medium and in the tube where no oil overlay was done. In case of fermentative 
organisms yellow color develops in both the tubes.
CONTROL
Glucose fermentation : Escherichia coli
Glucose oxidation : Pseudomonas aeruginosa
Non saccharolytic: Alcaligenes species.
2. DECARBOXYLATION OF LYSINE, ARGININE ORNITHINE 57
Decarboxylases are a group of specific enzymes which react with carboxyl portion 
of aminoacid forming alkaline reacting amines. The reaction is decarboxylation.  Each 
enzyme is specific for Lysine, Arginine and Ornithine.
PROCEDURE
   The organism was inoculated in four tubes. One having the basal medium without 
aminoacid for control. Other three tubes having lysine, arginine and ornithine each. All 
tubes were overlaid with liquid paraffin. All were incubated at 370C for 24 hours.
The control tube turned yellow indicating that the organism is viable and the test 
medium turning blue purple indicating positive result.
3. O–NITROPHENYL β - D GALACTOPYRANOSIDE 57
A dense suspension of the test organism grown in TSI agar was prepared in saline. 
About 1 drop of toluene was added to the suspension and 0.2ml of ONPG solution was 
added  to  the  suspension  and incubated  at  370C  β-galactosidase  producing  organism 
show yellow color after 1 hour or 18-24 hours incubation.
4. ACETAMIDE AGAR 11
The slant was inoculated with a portion of isolated colony and incubated at 370C 
overnight and was observed for color change from green to blue Tubes with negative 
result were further incubated for 7 days. 
5. GELATIN LIQUEFACTION TEST 57
Gelatin breakdown can be demonstrated by incorporating it in a buffered nutrient 
agar,  growing the culture and then flooding the medium with mercuric chloride that 
differentially precipitates either gelatin or its breakdown products.causing opacity in the 
medium with clear zones around gelatin-liquefying colonies 
ANTIBIOTIC SENSITIVITY20
Antibiotic  susceptibility  pattern  was  done  on  Mueller  Hinton  Agar  by  Kirby-
Bauer  disc  diffusion method as recommended by Clinical  and Laboratory  Standards 
Institute(CLSI).20  Himedia discs were used for disc diffusion testing.
Antibiotic Discs Contents
Amikacin 30µg
Gentamicin 10µg
Cephotaxime 30µg
Ceftazidime 30µg
Cefepime 30µg
Ciprofloxacin 5µg
Ofloxacin 5µg
Piperacillin 100µg
Piperacillin – Tazobactum 100/10µg
Imipenam 10µg
Meropenam 10µg
Aztreonam 30µg
                                                   
The control strains used were E.coli ATCC 25922 and Pseudomonas aeruginosa 
ATCC  27853  Overnight  broth  culture  compared  to  0.5  McFarland’s  was  used  as 
inoculum. After incubation at 37oC for 16-18 hrs, zone of inhibition was noted. Results 
were interpreted according to CLSI standard.
Multidrug resistant  (MDR) isolates of the nonfermenters were estimated MDR 
isolate was defined as resistant to three or more drugs of therapeutic relevance.
DETECTION OF EXTENDED SPECTRUM OF β -LACTAMASES 20,23
All nonfermenters that were resistant to cefotaxime and or ceftazidime were tested 
for Extended Spectrum of β-Lactamases.by the following methods:
Phenotypic confirmation test with Cephalosporin / clavulanate combination disks.20 
This  was  done  as  recommended  by  CLSI.  Mueller  Hinton  Agar  plates  were 
swabbed  with  test  organism  having  the  turbidity  equivalent  to  0.5  Mc  Farland’s 
standard. Aseptically cefotaxime disk (30µg), cefotaxime – clavulanic acid (30µg/10µg) 
ceftazidime (30µg) & ceftazidime clavulanic acid (30µg/10µg) were placed on surface 
of agar. The plates were incubated at 350C for 16-18 hours and diameter of zone of 
inhibition produced was recorded. A 5mm increase in zone diameter for combination 
disc than that when tested alone confirmed the presence of ESBL production.
ATCC Escherichia coli 25922 & Klebsiella pneumoniae ATCC 700603 were used 
as negative and positive control respectively.
DETECTION OF ESBL BY E-TEST
It is a plastic drug – impregnated strips, one end of which contains a gradient of 
ceftazidime  (MIC  test  range  0.5  to  32  µg/ml)  and  the  other  with  a  gradient  of 
ceftazidime plus a constant concentration of clavulanate (4 µg/ml). Similar strips were 
used for cefotaxime and cefotaxime / clavulanate. A 0.5 Mc Farland turidity standard of 
the organism was inoculated as a lawn culture on Mueller Hinton agar. E strips were 
placed on the agar surface and plate were incubated at 35°C for 16-18 hours.
INTERPRETATION
A > 8 fold reduction in cephalosporin MICs in the presence of clavulanate is taken 
as positive for ESBL.
DETERMINATION  OF  MINIMUM  INHIBITORY  CONCENTRATION  OF 
IMIPENAM AND MEROPENAM BY BROTH MICRODILUTION METHOD
The Minimum Inhibitory Concentration is the least amount of antimicrobial that 
will inhibit visible growth of an organism after overnight incubation.
MIC was determined by using Mueller Hinton broth as the medium in a microtitre 
plate. Serial dilutions of Imipenam and Meropenam were prepared in distilled water. The 
concentrations used were 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125 µg/ml. A 
young peptone water culture of the organisms corresponding to the concentration of 5x 
105/ ml is used as inoculum. A quality control strain of Pseudomonas aeruginosa ATCC 
27853 was included. The plate was incubated at 35.c for 16-18 hours.
RESULTS AND INTERPRETATION
MIC is expressed as the highest dilution which inhibited the growth as judged by 
the  lack  of  turbidity  in  the  tube.MIC  >  8µgm/ml  –  Carbapenam  resistant.  MIC  < 
8µgm/ml – carbapenam susceptible. Level of resistance to carbapenams were also noted. 
SCREENING FOR METALLOBETALACTAMASE PRODUCTION
Screening  for  metallobetalactamse  production  was  done  in  isolates  of 
nonfermenters  that  were  resistant  to  Imipenam and or  Meropenam.  Due  to  intrinsic 
resistance  to  carbapenams  mediated  by  resident  MBL  production,  isolates  of 
Stenotrophomonas maltophilia were not considered eligible for MBL screening.40,48 The 
methods used were:
MODIFIED HODGE TEST 62
The indicator organism,  Escherichia coli ATCC 25922, at a turbidity of 0.5 Mc 
Farland standard was used to inoculate the surface of a Mueller -  Hinton agar plate 
supplemented with zinc sulfate at a concentration of 70µgm/ml.and the test strain was 
heavily streaked from the centre to the plate periphery. After the plate was allowed to 
stand for 15 min at room temperature, 10 µg Imipenam disk was placed at the center and 
the  plate  was  incubated  overnight.  The  presence  of  a  distored  inhibition  zone  was 
interpreted as a positive result for carbapenam hydrolysis screening.
IMIPENAM – EDTA DOUBLE DISC SYNERGY TEST 62
Test organism was adjusted to the 0.5 Mc Farland standard and used to inoculate 
Muller Hinton agar plates. 10µg Imipenam disk was placed on the plate and a blank 
filter paper disk was place at a distance of 10mm (edge to edge). To the blank disk, 10µl 
of  0.5M  EDTA solution  (1,900  µg  of  disodium salt,  dihydrate)  was  added.   After 
overnight incubation, the presence of even a small synergistic zone was interpreted as 
positive.
IMIPENAM – EDTA COMBINED DISK TEST 113
Test  organisms  of  0.5  Mc  Farland  standard  were  inoculated  onto  plates  of 
Mueller– Hinton agar. A 0.5M EDTA solution was prepared. Two 10µg Imipenam discs 
and Meropenam discs were placed on the plate. 5µl of EDTA solution was added to one 
of the disc. The inhibition zones of the Imipenam and Imipenam + EDTA discs were 
compared after 16-18 hrs of incubation at 370C. An increase in inhibition zone of ≥ 7mm 
in combined disc than imipenam disc alone was considered as positive
MODIFIED HODGE TEST
DDST
DDCT
DETERMINATION.  OF  METALLOBETALACTAMASE  GENE  BY 
MULTIPLEX PCR METHOD 59,61,69
In this study, multiplex PCR was used to determine the gene for MBL production 
in  Ps.aeruginosa  isolates  that  were  resistant  to  carbapenams  PCR  was  done  using 
primers specific for MBL genes.
Cell lysates of the isolates were used as DNA template for colony lysate PCR. 
Around 5 – 10 colonies were suspended in 100µl  of  Milli  Q water  & boiled for  5 
minutes. It is then centrifuged at 10,000 rpm for 10 minutes. The supernatant provided 
templates for PCR reactions.
Forty  amplification  cycles  were  performed  with  an  automated  thermocycler 
according to the following format: Initial denaturation for 5 min at 94. C, 30 cycles of 
DNA denaturation for 30 s at 94.c, annealing for 30 s at 55.c and extension for 1.5 min 
at 72.c. The final cycle was followed by an additional 5 min at 72.c to complete partial 
polymerizations.  Amplified  products  were  run  using  horizontal  1.5  %  agarose  gel 
electrophoresis. The gel was visualized using a UV transilluminator. The amplified PCR 
products and 100 base pair DNA molecular markers were seen as bright fluorescent 
bands.
INTERPRETATION
A 261 bp corresoponds to VIM and 587 bp corresponds to IMP gene.specific 
oligonucleotides.
RESULTS
                     A total of 156 strains of nonfermenting gram negative bacteria (NFGNB) 
from different clinical samples were processed and grouped during the study period. 
Table-1
AGE DISTRIBUTION OF PATIENTS n= 156
Age No. of Patients Percentage
0-20 16 10.3%
21 – 40 80 51.3%
41 – 60 48 30.7%
>60 12 7.7%
Maximum number of isolates were in the age group of 21 – 40 years (51.3%) 
followed by 41 – 60 years (30.7%).
Table 2
GENDER DISTRIBUTION OF PATIENTS n = 156
Sex Number Percentage
                Male                110                  70.5%
               Female                 46                  29.5%
Males (70.5%) outnumbered females (29.5%)
Male: Female ratio = 2.4 : 1
Table 3
CATEGORY OF CASES n=156
Category Number Percentage
Community 
acquired
              14                   9%
Hospital acquired              142                  91%
Most  of  the  infections  associated  with  nonfermenters  were  hospital  acquired. 
(91%)
Table 4
SAMPLE DISTRIBUTION n=156
Sample Number Percentage
Pus 63 41.1%
Urine 48 30.2%
Tracheal Aspirate 22 14%
Blood 10 6.3%
Sputum 6 3.8%
Bronchoalveolar lavage 5 3.2%
CSF 1 0.7%
Drain 1 0.7%
TOTAL 156 100%
Pus (41.1%) was the predominating clinical sample harboring the nonfermenters 
followed by urine (30.2%) & tracheal aspirates (14%).
TABLE 5
SOURCE OF SAMPLES n=156
Specialty No. of Cases Percentage
Surgery 40 25.5%
Intensive care unit 29 18.6%
Urology 21 13.5%
Medicine 16 10.5%
Orthopedics 14 8.9%
Diabetology 10 6.5%
Thoracic Medicine 9 5.7%
Otorhinolaryngology 7 4.4%
Oncology 5 3.2%
Nephrology 4 2.6%
Neurosurgery 1 0.6%
Maximum number of the clinical samples infected by NFGNB were from Surgery 
wards (25.5%) followed by Intensive Care Unit (18.6%) & Urology (13.5%)
TABLE 6
RISK FACTORS ASSOCIATED WITH INFECTIONS BY NONFERMENTERS 
n=156
Risk Factors Number Percentage
Surgery/Trauma 31 23.8%
Catheter & Instrumentation 27 20.7%
Diabetes Mellitus 24 18.5%
ICU stay 22 16.9%
Prolonged antibiotic therapy 16 12.3%
Malignancy 5 3.9%
Transplantation 3 2.3%
Dialysis 2 1.6%
TOTAL 130 83%
Risk factor was present in 83% of the infections by NFGNB (p < 0.05) and the 
commonest risk factors associated with these infections were surgery (23.8%), catheters 
& Instrumentation procedures (20.7%), Chronic illness like diabetes mellitus (18.5%) 
and prolonged stay in ICU (16.9%).
TABLE 7
GROUPING OF NON FERMENTING GRAM NEGATIVE BACILLI
Group Number Percentage
Oxidase positive and Motile 101 64.1%
Oxidase positive and Nonmotile 2 1.9%
Oxidase negative and Motile 7 4.5%
Oxidase negative and 
Nonmotile
46 29.5%
TOTAL 156 100%
64.1% of the isolates were oxidase positive and motile
TABLE  8
SPECIATION OF NFGNB ISOLATED n=156
Clinical Isolates Number Percentage
Pseudomonas aeruginosa 92 58.9%
Acinetobacter.baumanii 46 29.5%
Stenotrophomonas.maltophilia 7 4.5%
Pseudomonas fluorescens 4 2.6%
Alcaligenes fecalis 3 1.9%
Weeksella virosa 2 1.3%
Burkholderia cepacia 2 1.3%
TOTAL 156 100%
Pseudomonas.aeruginosa  (58.9%) was  the  predominant  isolate  among  the 
nonfermenters,  followed  by Acinetobacter.baumanii  (29.5%)  S.  maltophilia  (4.5%),  
Ps.fluorescens  (2.6%), Alcaligenes  fecalis  (1.9%), B.cepacia  (1.3%),  and  Weeksella  
virosa (1.3%) 
TABLE 11
MULTI DRUG RESISTANT NONFERMENTERS n=156
Organism Total Number MDR Percentage
Ps.aeruginosa 92 71 77%
A.baumanii 46 36 78%
S.maltophilia 7 7 100%
B.cepacia 2 2 100%
Ps.fluorescens 4 1 25%
A.fecalis 3 1 33%
W.virosa 2 - -
Total 156 118 75.6%
75.6% of NFGNB were multidrug resistant.
TABLE 12
DRUG SUSCEPTIBILITY OF MDR STRAINS
DRUGS SUSCEPTIBLE RESISTANT P value
GENTAMICIN 5.1% 94.9% < 0.01
AMIKACIN 41.8% 58.2% < 0.01
CIPROFLOXACIN 38.8% 61.2% < 0.01
OFLOXACIN 33.7% 66.2% < 0.01
CEFOTAXIME 4.1% 95.9% < 0.01
CEFTAZIDIME 57.1% 42.9% < 0.01
PIPERACILLIN 12.2% 87.8% < 0.01
PIP-TAZO 65.3% 34.7% < 0.01
CEFIPIME 16.3% 83.7% < 0.01
AZTREONAM 23.8% 76.2% < 0.01
IMIPENAM 82.7% 17.3% < 0.05
MEROPENAM 82.7% 17.3% < 0.05
Multidrug resistant  isolates  were susceptible to carbapenams,  ceftazidime  and 
piperacillin-  tazobactum.  Maximum  resistance  was  seen  with  cefotaxime  and 
gentamicin.
TABLE 13
ESBL PRODUCTION IN NONFERMENTERS n=156
Organism Total No.
ESBL 
Producers
Percentage
Ps.aeruginosa 92 63 68.4%
A.baumanii 46 32 69.5%
S.maltophilia 7 7 100%-
P.fluorescens 4 1 25%
B.cepacia 2 2 100%
A fecalis 3 1 50%
W.virosa 2 - -
Total 156 106 67.9%
67.9% of NFGNB were ESBL producers. 
TABLE 14
ESBL PRODUCTION IN SAMPLES n=156
Samples Total No. ESBL Percentage
Pus 63 47 74%
Urine 48 33 70%
Trachea 22 16 72%
Blood 10 4 40%
Sputum 6 3 50%
BAL 5 3 60%
CSF 1 -- -
Drain 1 - -
Total 156 106 67.9%
Majority of samples with ESBL isolates were Pus (74%), tracheal aspirates (72%). 
and Urine (70%),
TABLE 15
DRUG SUSCEPTIBILITY OF ESBL ISOLATES
DRUGS SUSCEPTIBLE RESISTANT P value
GENTAMICIN 6.7% 93.7% < 0.01
AMIKACIN 44% 56% < 0.01
CIPROFLOXACIN 34.7% 64.3% < 0.01
OFLOXACIN 30.7% 69.3% < 0.01
CEFOTAXIME 5.3% 94.7% < 0.01
CEFTAZIDIME 41.3% 58.7% < 0.01
PIPERACILLIN 10.7% 89.3% < 0.01
PIP-TAZO 60% 40% < 0.01
CEFIPIME 17.3% 82.7% < 0.01
AZTREONAM 25.2% 74.8% < 0.01
IMIPENAM 82.7% 17.3% < 0.05
MEROPENAM 82.7% 17.3% < 0.05
ESBL  producing  isolates  were  susceptible  to  carbapenams,  amikacin  and 
piperacillin-tazobactum. Maximum resistance was seen with cefotaxime and gentamicin.
TABLE 16
DISTRIBUTION OF ACQUIRED CARBAPENAM RESISTANT ORGANISMS 
Organisms Total No. Carbapenam resistant isolates Percentage
Ps.aeruginosa 92 9 9.7%
A.baumanii 46 3 6.5%
 S.maltophilia 7 - -
P.fluorescens 4 -
B.cepcia 2
A.fecalis 3 -
W.virosa 2 -
Total 156 12 7.7%
7.7%  of  strains  were  acquired  carbapenam  resistant  organisms.  Predominant 
organisms were Ps.aeruginosa (9.7%) & A.baumanii (6.5%).
TABLE 17
PATTERN OF CARBAPENAM RESISTANCE  n=12
RESISTANCE MIC µgm/ml NO. PERCENTAGE
High - level >32 7 58%
Low - level 8 - 32 5 42%
High level resistance to carbapenams was found in 7 isolates. Low level resistance 
was found in 5 isolates.
TABLE 18
ACQUIRED MBL PRODUCTION IN NONFERMENTERS
ORGANISM TOTAL NO
CARBAPENAM 
RESISTANT
MBL
P.aeruginosa 92 9 5(5.43%)
A.baumanii 46 3 2(4.34%)
S.maltophilia 7 - -
P.fluroscens 4 - -
A.fecalis 3 - -
B.cepacia 2 - -
W.virosa 2 - -
TOTAL 156 12(7.7%) 7(4.48%)
4.48% of isolates were MBL producers. 
TABLE 19
RESULTS OF PCR IN IMEPENAM RESISTANTPSEUDOMONAS n=9 
MBL GENE TOTAL NO OF CASES PERCENTAGE
Positive 5 55%
Negative 4 45%
The  gene  responsible  for  metallobetalactamase  production  was  observed  in  5 
isolates (55%)
TABLE 20
PATTERN OF GENE OBSERVED IN MBL PRODUCING 
Ps. aeruginosa  n=5
TYPE OF MBL GENE TOTAL NO OF CASES PERCENTAGE
IMP 2 40%
VIM 3 60%
VIM type isolates (60%) were predominant than IMP type isolates.
TABLE 21
COMPARISON OF MBL DETECTION BY DIFFERENT METHODS 
Organism No
Modified 
Hodge 
test
Double disc 
synergy test
Double disc 
combined 
test
PCR
+ve _ve +ve _ve +ve _ve +ve _ve 
P.aeruginosa 9 3 6 4 5 5 4 5 4
A.baumanii 3 2 1 2 1 2 1 Not 
done
Not 
done
Total 12 5 7 6 6 7 5 5 4
Sensitivity and specificity of Modified Hodge test for P.aeruginosa were 60% and 
93.4% respectively  and  for  the  EDTA –  disk  synergy  test  sensitivity  was  80% and 
specificity  95.3% whereas  for  the  EDTA-  combined  disc  test  both  were  100% The 
differences  in  sensitivity  and  specificity  between  these  tests  were  statistically 
significant(p<0.01 by chi-square test) 
All the three tests were equally sensitive and specific for A.baumanii 
DISCUSSION
Non  fermenting  Gram  Negative  bacilli  (NFGNB)  are  being  isolated  with 
increasing frequency from clinical specimens and clinical problems posed by their multi 
drug resistance in recent years has led to the interest in the present study.
One hundred and fifty six isolates of non fermenting gram negative bacilli were 
taken  from  various  clinical  samples  like  pus,  urine,  endotracheal  aspirates,  blood, 
sputum, cerebrospinal fluids and drain tube and evaluated for their role in infections in 
hospitalised patients including the characteristics of their drug resistance.
Analyzing the age group, higher incidence of infection by NFGNB was seen in 
the age group of 21-40 years (51.3%) (Table 1). This was comparable with the study by 
Meharwal et al from Chandigarh (53%) 70 It can be attributed to the increased activity of 
the age group and higher chance of exposure to infections.
The incidence of infections by nonfermenters is very high in males (70.5%) as 
compared to females (29.5%) (Table 2). This correlated with the study by Chacko.B et al 
who observed 66.6% of males to be affected as compared to (33.3%) of females 17. The 
increase in male to female ratio (2.4:1)  could be due to the involvement of outdoor 
activities by males and therefore increased chance of exposure to infections.
The present study shows a higher rate of hospital acquired infections (91%) by 
nonfermenters  than  community  acquired  infections  (9%)  (Table  3).  Studies  like 
Meharwal  et  al  (88%),  from India  and  Marcus.et  al  (92%)  from Israel  support  this 
finding70, 68.
In the current study, community acquired infections were most commonly caused 
by  Pseudomonas (7.05%) followed by  A.baumanni (1.92%) The infections were otitis 
externa  ,  chronic  suppurative  otitis  media  and  urinary  tract  infections.Urinary  tract 
infection  was  the  commonest  community  acquired  infection  by  nonfermenters.  This 
finding is comparable with the studies by Paraskaki et al (6.5%), Marcus.et al (8%) ,  
Gilad J et al, (8% & 2%) and Badura et al( 7%).78, 68, 41, 10
Among the clinical samples, nonfermenters were predominantly observed in pus 
samples (41.1%) followed by urine (30.2%) and tracheal aspirates (14.1%)in the present 
study(Table 4). Kharangate et al from India reported 50% incidence in pus samples.54 
Vijaya et al from India reported a lower incidence of 32.4% in pus samples107.Veenu et al 
reported 29% incidence in urinary tract infections.106 Gladstone et al from CMC Vellore 
showed a higher incidence in endotracheal aspirates (42.4%) due to large number of 
samples 42.
In the present study, majority of the isolates of nonfermenters were from General 
Surgery wards (25.5%).(Table 5) A study by Anupurba et al from India reported higher 
prevalence  of  29% isolations  in  surgery  wards6.  Another  study  by Ezeltahawy from 
Saudi Arabia also observed 25% isolations from General surgical wards29.This might be 
due to prolonged stay in hospital following an operation resulting in colonization and 
subsequent  infection  The  second  highest  source  observed  in  the  present  study  was 
intensive care unit (18.6%) followed by urology units (13.5%). These data clearly state 
the importance of the infections caused by nonfermenters in the intensive care settings. 
Several studies also report a higher incidence in these units.  (Trautmann et al -50% , 
Aikaterini Mastoraki et al- 15%, Gladstone et al -12.2%) 105, 3, 42
Risk factors for development of infections by nonfermenters were present in 83% 
cases (p < 0.05) in this study while Meharwal et al also reported presence of risk factors 
in 87.2% of infections by these organisms70 The significant risk factors in the present 
study  were  surgery/trauma  (23.8%)  catheters/instrumentation  (20.7%)  and  diabetes 
mellitus  (18.5%).  and  stay  in  the  intensive  care  unit  (16.9%).  (Table  6)  .The 
identification of ICU as a strong risk factor is not unexpected. Studies by .Joshi et al  
(30.8%) & Ezeltahawy et al. (34%) have identified a longer stay in intensive care unit as 
a risk factor  51, 29 . In addition, in the present study, variables related to hospitalization 
and invasive  procedures  like  intubation,  prolonged therapy  with  antibiotics,  catheter 
lines,  dialysis,  malignancy  and  transplantation  were  identified  as  risk  factors  for 
infections caused by NFGNB. as observed in the studies by. Falagas et al, Saad Nseir et 
al, Nicholas et al 32, 94, 75 
Grouping of NFGNB (Table 7) showed 64.1% of the isolates belonging to oxidase 
positive  and  motile  group  in  the  present  study  as  compared  to  Veenu  et  al.106 
Pseudomonas aeruginosa was  the predominant  isolate  (58.9%) (Table  8)  among the 
nonfermenting  gram  negative  bacilli  observed  in  the  present  study  followed  by 
Acinetobacter. baumanii (29.5%), Stenotrophomonas. maltophilia (4.5%), Pseudomonas 
fluorescens (2.6%)  Alcaligenes  faecalis (1.9%),  Burkholderia  cepacia (1.3%),  and 
Weeksella  virosa (1.3%),  Kharangate  et  al  from  India  reported  56%  isolation  of 
Ps.aeruginosa 54 Taneja et al, from  Chandigarh, India found Ps aeruginosa (51%) as the 
predominant isolate followed by  A.baumanii (31%), and  A faecalis (7%)100. Similar to 
the  present  study,  a  study  from  Saudi.Arabia  by  Ezeltahawy  et  al.  identified  Ps.  
aeruginosa as  the  most  common  isolate  (56%)  followed  by  A.baumanii (34%)  & 
S.maltophilia (.6%)29. Wang H et al from China reported most predominant pathogens as 
Ps.aeruginosa (46.9%), Acinetobacter species (31%) & S.maltophilia (9.2%).110
PSEUDOMENAS AERUGINOSA (Table 9)
In the present study, out of the 92 isolates of  Ps aeruginosa 41 isolates (44.6%) 
were from pus samples comprising wound swabs, ulcers and ear swabs This is similar to 
the study by Basu et al who reported  40% isolates from pus samples12. Other Indian 
reports by Veenu et al & Behera et al showed higher isolation rate of 53.4% & 66.7% 
respectively.106,13 A report by Kiani et al from Pakistan also showed  Ps.aeruginosa as 
commonest isolate from pus samples (55%).55  However reports by Frank et al from 
USA  and Olayinka from Africa were less at 12% and 33%.35, 77 Higher rate of infections 
found  here  compared  to  western  studies  necessitates  the  implementation  of  proper 
infection control measures.
Ps. aeruginosa was next commonly present in urine samples – 24 isolates among 
92 isolates (26%). It is an opportunistic pathogen in urinary tract infections accounting 
upto 40% of infections in the hospital 44. The rate in the present study was higher than 
that  reported in  Taiwan (11%).84 but  comparable  to the Indian study by Veenu et  al 
(29%).106 Similar to the studies in literature (Meharwal et al - 45.5%  Dedeic et al -16%, 
Milan et al -10% , Aaron et al -30% & Tabibian et al - 38%)  Ps.aeruginosa infection 
were associated with catheter related, cytoscopy related & other urinary tract procedures 
(20%)in the present study.70, 24, 72, 1, 99
Investigations have shown that  Ps.aeruginosa were significant  pathogens form 
endotracheal aspirates especially in ICU42. This study by Gladstone et al from Vellore 
showed  an  incidence  of  42.8%  of  drug  resistant  Ps.aeruginosa from  endotracheal 
aspirates. The present study shows 10 / 92 isolates (11%) from endotracheal aspirates 
which is lower than the previous study due to lesser number of samples but correlates 
with the study by Chien Liang Wu et al (10%)19 A study by Jonaidi et al from Iran 
showed 32% isolations and  Ps aeruginosa as the most common isolate from tracheal 
specimens.48 Culture  of  endotracheal  aspirates  is  a  valuable  tool  in  the diagnosis  of 
ventilator  associated  pneumonia  where  NFGNB  especially  Ps.  aeruginosa is  a 
significant pathogen (Furtado et al & Aikaterini Mastorati et al).37, 3
In the present study, 8.8% of  Ps aeruginosa isolates were from blood cultures 
similar to the Indian study by Vijaya et al  (8%)107 SENTRY survey of blood stream 
infections due to gram negative bacilli collected in USA, Canada and Latin America 
showed an incidence of 10.6% of Ps.aeruginosa bacteremia25   A report by Mayo clinic 
in 2008 showed an incidence (10.2%) comparable to the present study 65
Four out of 92 (4.4%) isolates of  Ps.aeruginosa were from sputum samples and 
3/92  (3.3%)  from  bronchoalveolar  lavage  samples.  The  predisposing  factors  in  the 
respiratory  tract  observed  in  the  present  study  were  COPD,  chronic  bronchitis  and 
underlying chronic diseases. Various studies by Po-Ren Hseuh et al,  Italy, Aikaterini 
Mastoraki et al (6%), Veenu et al (9 %) , Ferrara et al (5%), Arora et al (12%). show that 
Ps. aeruginosa is frequently isolated from respiratory  tract.85, 3, 106, 33, 9,  
Ps.aeruginosa is  an  unusual  cause  of  bacterial  meningitis  associated  with 
immunosuppressed patients. In the present study one isolate each from CSF(1.08%) and 
drain tube (1.08%)  was observed comparable to the study by Chi et al. who showed 
Ps.aeruginosa as  the  most  common  isolate  from  shunt  infections.18 A  study  by 
Damsbrauskiene et al found 3 isolates of P.aeruginosa in CSF.21
In  the  present  study,  88%  of  Ps.  aeruginosa isolates  were  susceptible  to 
Imepenum & Meropenam,(Table 10) which was similar to Indian studies by Prakesh et 
al  86% & Anupurba et  al  84%86,  6 An Italian study also reported 81% susceptibility 
similar  to present  study.  30 Susceptibility to Piperacillin – Tazobactum in the present 
study  was  82.6%  comparable  to  the  study  in  Canada  conducted  in  the  year  2008 
(80.5%)108. A study in India by Basu et al in the year 2009 also reported high sensitivity 
to  Piperacillin  –  Tarobactum12 The  susceptibility  rate  of  P.  aeruginosa  isolates  to 
amikacin (61.9%), ceftazidime (65.2%), and ciprofloxacin (42.3%) in the present study 
were relatively low compared to the sensitivity pattern to these drugs reported world 
wide. In US more than 90% of the isolates were susceptible to amikacin, 80-90% of 
isolates were susceptible to ceftazidime while 70-80% of isolates were susceptible to 
ciprofloxacin 53 In Trinidad and Tobago 80 % isolates were susceptible to ceftazidime34. 
Reports from France have shown P. aeruginosa susceptibility rates of 78.5% and 61.7% 
to ceftazidime and ciprofloxacin, respectively15.. Studies in China & India gives results 
similar to the present study - 68% and  63% to ceftazidime and amikacin  111, 100 In the 
current study, high rate of resistance was seen with Gentamicin (71.8%) and cefotaxime 
(87%). similar to reports from India by Veenu et al (69% & 75%) and, Anupurba et al  
(75% & 82%)  106,  6.  This is much higher compared to reports from USA  (30%) and 
Trinidad (12 %) 53, 31. This shows the selective pressure from the use of these agents in 
empirical therapy in India as the main determinant for the emergence of drug resistant 
strains.
ACINETOBACTER BAUMANII (Table 9)
The next predominent isolate was A.baumanii in the present study. A total of 46 
out of 156 NFGNB were isolated accounting for 29.5%  Fourteen from pus, 19 from 
urine, 2 from blood, 8 from tracheal aspirates, 2 from bronchoalveolar lavage. , and 1 
from sputum 
A.  baumanii as  major  species  of  Acinetobacter,  isolated  from this  hospital  is 
reportedly a major pathogen responsible for nosocomial infections in other parts of the 
world also 83.
Urinary  samples  (41.3%) were  the  predominant  among the  clinical  specimens 
showing  infection  with  A baumanii.  This  is  in  accordance  with  Indian  reports  by 
Meharwal et al (39%) & Taneja et al (41%).70, 100
Isolates in pus in this study was 30.4% comparable to Indian study by Joshi et al 
(27.5%) and a study from Pakistan reporting Acinetobacter spp as one of the commonest 
isolates from wound infections.51, 55
The present study shows A.baumanii as a major pathogen in Intensive care units 
as well with an isolation rate of 17.3% in endotracheal aspirates.similar to the reports in 
Italy  (Ferrara et al- 16%) and .Gladstone et al (19%)  from CMC Vellore India. 33,  42 
Literature gives a morality rate going upto 70% associated with ventilator associated 
pneumonia  by  A.baumanii.74,  66 No  mortality  was  observed  in  the  present  study  in 
endotracheal aspirates..
Epidemiological studies on blood stream infections show A.baumanii as the tenth 
most common etiologic agent at 1.3% of these infections47.  The present study shows 
4.3% of  A.baumani. isolates from blood culture samples comparable to a report from 
India by Arora et al (5.4%) but less than the reports from USA, France, Belgium and 
Germany ranging from 7-9% (Lahiri  et  al)  8,  60 Invasive procedures like intravenous 
catheterization was a major risk factor in the study by Joshi et al and it was observed in 
this study as well.51
Isolation rate  from bronchoalveolar  lavage  and sputum samples  were  4.4% & 
2.1%.comparable to the studies by Patwardhan et al, at 7% and 6 %.respectively79
There have been isolations from CSF and other body fluids 74 but no such isolate 
is reported in the current study.
A.baumanii is an organism which exhibits high resistance to antibiotics in hospital 
environment.  In  the  present  study  93.4% of  isolates  were  sensitive  to  Imipenam & 
Meropenam,(Table 10), 86.9% to Piperacillin-Tazobactum, 69.5% to Amikacin, 48.6% 
to ceftazidime, while cefotaxine & gentamicin showed maximum resistance at 76% and 
85%. This finding is nearly comparable with Aroma et al, Ferrara et al from Italy and 
Jones et al 7, 33, 50
S.MALTOPHILIA (Table 9)
S.maltophilia is  an  emerging  nococomial  pathogen  in  hospital  settings.  The 
significance of this organism lies in its intrinsic multidrug resistance.  92. Seven out of 
156 (4.5%) nonfermenting gram negative bacilli were observed in this study. This is less 
compared to the reports in China (9.2%)111. However Indian reports found 3.35% (Vijaya 
et al) & 1% (Meharwal, Taneja, & Veenu et al) isolations among NFGNB from clinical 
specimens. 107, 70, 100, 106
Four isolates were obtained from endotracheal aspirates in this study. A study by 
Chien Liang Wu et al had reported S.maltophilia as the third most common organism (2 
isolates) isolated from endotracheal aspirates.19 Kollef et al reported that isolation of this 
high  risk  pathogen  is  an  important  predictor  of  mortality  in  Ventilator  Associated 
Pneumonia.66
In the present study 3 isolates were obtained from pus (,2 from diabetic foot ulcer 
&1  from postoperative wound swab). similar to the studies by Veenu et al.  106.Studies 
have shown that S.maltophilia is a frequent isolate from wounds and other skin lesions 73
S.maltophilia is  highly  resistant  to  many of  the antibiotics  commonly  used in 
hospital  settings73  In  the  present  study,(Table10)  these  isolates  were  sensitive  to 
quinolones (57%), and cotrimoxatole (100%), Resistance was observed with betalactam 
agents – ceftazidime (82%), and cefotaxime (100%).as observed by Robert et al92
P.FLUORESCENS(Table 9)
P.fluorescens is also a common isolate in various clinical specimens mentioned in 
different literature studies 49, 74
In the present study  4/156 (2.6%) strains were obtained. All of them were isolated 
from pus. A study by Veenu et al reported 6 isolates from pus106. Sheretz et al reported 
2.38% of isolates.95 Although isolates from blood culture have been reported, the present 
study did not give any blood isolate.
These organisms (Table10) were susceptible to carbapenams (100%) Amikacin 
(100%), Ceftazidime(100%), and Piperacillin – Tazobactum (100%) Studies in literature 
show sensitivity of these organisms to betalactam agents & carbapenams 74
BURKHOLDERIA CEPCIA (Table 9)
Burkholderia cepacia has emerged as a significant respiratory pathogen 92. Study 
done in Chandigarh show majority of these isolates from blood.39 In the present study 
one  each  were  isolated  from pus  and  sputum.  The  isolation  of  this  organism from 
diabetic foot ulcer was significant in this study.
B.cepacia is  an  important  pathogen  isolated  from  sputum  of  cystic  fibrosis 
patients 90 In the present study one isolated was obtained from sputum 
These organisms (Table10)  were sensitive to  carbapenams (100%),  quinolones 
(50%) and ceftazidime (50%).A report by V.Gautam et al found a similar susceptibility 
profile with resistance to aminoglycosides as observed in the current study.39
ALCALIGENES FECALIS (Table 9)
Alcaligenes  fecalis is  a  pathogen  in  hospital  acquired  infections  especially  in 
persons with underlying diseases74. In the present study 3/156 strains were isolated from 
urinary tract infections. Vijaya et al and Veenu et al isolated 3 and 1 isolates from urine 
respectively.106, 107 
In the present study (Table8) these ioslates were sensitive to Amikacin (100%), 
ceftazidime (100%) and carbapenams (100%). Resistance was observed to quinolones (!
00%) and gentamicin(50%) comparable to the study by Meharwal et al.70.
WEEKSELLA VIROSA (Table 9)
Flavobactericeae  have  been  recoverd  from  hospital  environment  causing 
nosocomial outbreaks.57
In  the  present  study  2  Weeksella  virosa isolates  were  obtained  from  urine. 
Meharwal et al isolated one strain of W.virosa from urine.70 
In the present study these organisms (Table10) were susceptible to carbapenam 
(100)%), ceftazidime (100%) Amikacin (100%). Reports in literature showed  sensitivity 
to piperacillin-tazobactum & ciprofloxacin. similar to the present study74
MULTIDRUG RESISTANT NONFERMENTERS (Table11)
Multidrug  resistance  is  a  major  problem  with  non  fermenting  gram  negative 
bacilli  and so the infectionjs  caused by them are very difficult  to be treated.  In  the 
present study 75.6% of NFGNB were resistant to 2 or more drugs of relevance. and Ps 
aeruginosa (77%), A. baumanii (78%) & S.maltophilia (100%) were the most common 
multidrug resistant strains. This is higher than the studies in India reported previously in 
the year 1998 (Vijaya et al) and 2000.(Veenu et al)  at  31% & 62% respectively and 
comparable  to  the  study  .by  Patwardhan  et  el  in  2008  who  showed  >68%  of 
Pseudomonas isolates and >90% Acinetobacter isolates were multidrug resistant.107,106,79 
While S.maltophilia is intrinsically resistant to antibiotics, Ps aeruginosa & A.baumanii 
acquire  resistance  by  many  different  mechanism  like  Extended  spectrum  of 
betalactamases  (ESBL)  and  Metallobetalactamases(MBL).  This  is  of  concern  as 
efficacious antimicrobial options are limited.47 The present study showing Acinetobacter 
as more multidrug resistant than Pseudomonas correlated with the studies by Tanya et al 
(53% and 49%) and Homer et al ( 62% and 58%)101,  46 Multidrug resistant organisms 
were  susceptible  to  Piperacillin  –  tazobactum   (62.3%),  and  carbapenams  (82.7%) 
Maximum  resistance  was  seen  with  gentamicin(94.9%)  and  cefotaxime.(95.9%) 
(Table12)
Extended spectrum of betalactamase (Table13)
Extended  spectrum  of  betalactamase  production  was  observed  in  67.9%  of 
NFGNB. S.maltophilia(100% , B.cepacia(100%),Ps.aeruginosa (68.4%) & A.baumanii 
(69.7%)  were  the  predominant  ESBL  producers.  comparable  with  the  report  by 
SridharRao(61.7%)98.  While  S.maltophilia  and  B.cepacia  show  intrinsic  resistance  , 
ESBL  production  by  Ps.aeruginosa  and  A.baumanii  is  significant92 All  the  ESBL 
producers were multidrug resistant. Maximum sensitivity among the ESBL producers 
was  seen  with  Imepenam  (82%)   followed  by  piperacillin  –  Tazobactum  (60%) 
(Table14) as seen in the studies conducted by Brauers et al and Freshteh et al16,36 
Maximum ESBL production was found in pus (74%), tracheal aspirates(72%) and 
urine samples(70%), (Table15).similar to the reports by RituSinghal et al  91These data 
shows an increase in the prevalence of ESBL producing organisms in India.
Pan drug resistant NFGNB 
Pan drug resistant isolates in the present study was seen in 7.7% (12/156) strains. 
Ps.aeruginosa &  A.baumanii were the most  common isolates.  Various studies in the 
literature show similar  reports  (Obritsch et  al  -9%, Aikaterini  Mastoraki  et  al  -12%, 
Falgas  et  al  -9%)76,  3,  31.  Antiobiotics  to  which  these  strains  were  resistant  were 
carbapenams,  third  generation  cepahalosporins,  Piperacillin,  Fluoroquinolones  and 
aminoglycosides. 
Carbapenam resistant NFGNB (Table 16) 
Acquired carbapenam resistance was observed in 7.7% strains (12/156 strains) 
Stenotrophomonas posseses intrinsic carbapenamase resistance and hence Ps aeruginosa 
(9.7%) and  A.baumanii (6.5%) were the most common acquired carbapenam resistant 
organisms.40,48 The incidence is lesser compared to study by Taneja et al (36.4%) but 
comparable to the report by Berges et al (7.2%), Prakash (8.1%), Kanungo et al from 
Pondicherry (10%) and,Gladstone et al (12.2%) 14,100,86, 52, 42,These data show an emerging 
resistance to carbapenams in this tertiary hospital. All the carbapenam resistant isolates 
were multidrug resistant.  They were susceptible to colistin & polymyxin.B.  Studies 
show that potentially toxic drugs like polymyxin B & colistin remained the only option 
among the drugs for the treatment of PDR isolates. ( Michaelopoulas et al, Koomanachi 
et al, Po-Ren Hseuh et al, Hachem et al)71,56, 83, 43
In the present  study (Table 17)high level  of  resistance  >32 MIC ugm/ml was 
observed in 7 isolates and low level 8 - 32 MIC ugm/ml found in 5 isolates. compared to 
the study by Jones et al and Massaru et al  who shoerd High level resistance can be 
caused by MBL enzymes and low level resistance is associated with reduced uptake of 
drug as a result of loss of porin Opr D 50, 69
METALLOBETALACTAMASE PRODUCING NFGNB (Table 18)
The present study shows 4.48% of total NFGNB as MBL producers.Of these 5 
isolates of Pseudomonas aeruginosa (5.43%) were confirmed to be positive by PCR and 
2 isolates  were  A.baumanii (4.34%)  Various  studies  across  the world,  has  reported 
MBL production ranging from 2%-60% 109. Indian reports by Navneeth et al show 12% 
of  MBL production  and  Agarwal  et  al  in  2008  reported  an  incidence  of  8%  Ps.  
aeruginosa strains to produce MBL.42,2 A study in Korea showed MBL production in 
10% of Ps. aeruginosa isolates and a  study in Japan showed 1.9% of MBL production 
in A.baumanii isolates 26, 40
In the present study MBL production was observed in tracheal aspirates(13%), 
followed  by  blood  samples(20%)  and  diabetic  foot  ulcer  (3%)in  the  present  study 
compared to that by Gian Marria (13%,17%,10%) respectively.40 Organisms with MBL 
production are associated with high mortality rate 82  In the present study, one mortality 
was observed in a renal transplant patient from whom MBL producing A.baumanii was 
isolated from blood culture sample. All the MBL isolates were sensitive to colistin and 
polymyxin B similar to the studies by Yoo Chul et al, and Hachem et al 114, 43
Molecular  analysis  (Table  19  and  20)  by  Multiplex  PCR  performed  on  the 
cabapenam resistant Pseudomonas isolates revealed 2 types of MBL genes circulating in 
this hospital –bla VIM and bla IMP.   bla VIM were more prevalent (3 isolates) similar to the 
study by Luzzare et al (4 isolates) than bla IMP (2 isolates) similar to the study by Masaru 
et al (2 isolates) and Gian et al  64,  69,  40.This data suggests the emerging resistance by 
carbapenamase production in NFGNB in this tertiary care hospital Rapid dissemination 
of MBL producer is a danger as we are left with the option of using potentially toxic 
drugs like Colistin & Polymyxin B for treatment of infections with MBL producers apart 
from  the  high  mortality  associated  with  them.This  necessitates  not  only  the 
implementation  of  surveillance  studies  but  also  proper  and  judicious  selection  of 
antibiotics in a tertiary care hospital 
Of the various methods used to detect MBL production(Table 21) Double Disc 
Combined.  Test  with  imipenam  &  imepenam  EDTA  showed  7  isolates  as  MBL 
producers. Double Disc Synergy Test showed 6 isolates as MBL producers. Modified 
Hodge Test showed 5 isolates as MBL producers. The present study observed DDCT to 
have sensitivity and specificity of 100% in Pseudomonas isolates compared to the PCR 
as gold standard. This study showed DDCT as the simple, inexpensive and reproducible 
functional screening test for MBL production in Ps.aeruginosa. Various studies by Ting-
ting Qu et al, Pitout et al, Dongeun Yong et al, Behera et al , Lee et al, and Berges et al 
have shown Double Disc combined and Synergy Tests as better methods / methods of 
choice to detect the MBL.production in the absence of PCR. 103, 88, 26, 13, 62, 14
MANAGEMENT OF INFECTIONS BY NFGNB
The  prevalence  and  sensitivity  of  nonfermenters  often  varies  between 
communities, hospitals in the same community and among different patient populations 
in the same hospital. Faced with these variations, the physician in clinical practice has 
the responsibility of making clinical judgments and should have access to recent data on 
the prevalence and antimicrobial resistance pattern of commonly encountered pathogens. 
It  is  therefore  important  to  institute  a  system  for  the  surveillance  of  antimicrobial 
resistance  that  will  involve  the  collection  and  collation  of  both  clinical  and 
microbiological data. The present study observed highest resistance of NFGNB against 
cefotaxime & gentamicin antibiotics which are commonly used drugs This necessitates 
the judicious use of these antibiotics in empirical therapy. Maximum sensitivity was 
observed  with  newer  agents  like  carbapenams  and  pipercillin-tazobactum.  Moderate 
sensitivity  was  seen with  aminoglycosides  and fluroquinolones.  Major  risk  of  using 
monotherapy is the emergence of antibiotic resistant bacteria as observed in the present 
study  which  showed  high  rate  of  multidrug  resistance  and  ESBL  producers. 
Carbapenamase  resistance,  though  not  high  was  still  observed  as  an  emerging  drug 
resistant mechanisms in the NFGNB from this hospital. Antibiotic therapy either empiric 
or  documented is based upon antibiotic combination supplemented by knowledge of 
local epidemiology of resistance and susceptibilities in choosing a suitable combination. 
Therefore  combination  antibiotic  therapy  like  piperacillin-tazobactum,  quinolones-
amikacin,  imipenam-amikacin  would  be  an  ideal  choice  of  therapy  on  the  basis  of 
antibiotic  susceptibility  testing.as  observed  in  this  study  along  with  an  adequate 
infection control measures especially in the surgical and ICU units 6,15,28,34,48,106
SUMMARY
1. A total of 156 strains of NFGNB from various clinical samples were studied for 
their role in hospital infections.
2. Higher incidence of nonfermentative isolates was observed in the age group of 
21-40 years (51.3%) with a preponderance in males.(70.5%)
3. Hospital  acquired  infections  were  more  compared  to  community  acquired 
infections  (91%)  and  Pus  samples  (41.1%)  were  the  predominant  among  the 
various clinical samples harboring nonfermenters.
4. Predominant source of these infections were from surgical wards.(25.5%) 
5. Infections by NFGNB were associated with a higher number of risk factors.(83%) 
(p < 0.005) and Intensive Care Units formed a significant source of infections by 
these organisms(16.9%)
6. Pseudomonas  aeruginosa was  the  predominant  isolate  (58.9%)  among  the 
nonfermenting  gram  negative  bacilli,  followed  by  A.  baumanii (29.5%) 
S.maltophilia (4.5%),  Pseudomonas  fluorescens (2.6%)  Alcaligenes fecalis 
(1.9%), Burkholderia cepacia  (1.3%), Weeksella virosa ( 1.3%), 
7. Pseudomonas  aeruginosa was  predominantly  isolated  from  pus  (44.6%), 
A.baumanii from  urine  (41.3%),  S.  maltophilia from  tracheal  aspirates 
(57.2%)  ,Weeksella  virosa from  urine,  Pseudomonas  fluorescens  from  pus, 
Alcaligenes fecalis  from urine Burkholderia cepacia from pus and sputum
8. The antibiotic susceptibility pattern of the isolated nonfermenters revealed 87.8% 
sensitivity  to  Imipenam and Meropenam,  followed by Piperacillin-Tazobactum 
(83%),  ceftazidime  (59.6%),  amikacin  (62.8%)  and  quinolones  (53.2%). 
Resistance was seen against cefotaxime (80.8%), and gentamicin (72.5%), 
9. Incidence of multidrug resistant nonfermenters was 75.6%
10. 7.7%  of  nonfermenters  were  pandrug  resistant  showing  resistance  to  all 
commonly used antibiotics.
11. Extended spectrum of betalactamase production was observed in 67.9% of the 
strains.and majority of these isolates were from pus samples (74%) followed by 
tracheal aspirates (72%) and urine (70%)
12. Acquired Metallobetalactamase production was seen in 4.48% of NFGNB and 
58.3% of carbapenam resistant  isolates.  Pseudomonas aeruginosa (5.43%) and 
A.baumanii (4.54%) were the predominant MBL producers. Blood sample (20%) 
was the predominant sample harboring MBL producers.
13. Double  disc  combined  test  method  was  a  better  method  of  detection  of 
metallobetalactamase production phenotypically with a sensitivity and specificity 
of 100%
14. Molecular characterization of MBL production revealed prevalence of VIM like 
isolates (60%)of Ps aeruginosa than IMP like isolates(40%)
15. Combination  therapy  of  piperacillin-tazobactum,  quinolones-aminoglycosides, 
and imipenam–aminoglycosides was recommended for treatment of infections by 
nonfermenters.
16. Potentially  toxic  agents  like  Colistin  and  Polymixin  B  were  the  only  option 
available for treating MBL isolates
CONCLUSION
Observations  from  the  present  study  showed  the  aerobic  NFGNB  which  are 
usually  considered  as  contaminants  are  now  emerging  as  important  nosocomial 
pathogens. The various clinical specimens from which they were isolated proved their 
existence in all  sites leading to a range of diseases.  Different sensitivity pattern and 
multidrug resistance exhibited by nonfermenters pose a great problem in treating these 
infections. ESBL and MBL production by these organisms lead to high morbidity and 
mortality as we are left with the only option of treating them by potentially toxic agents 
like Colistin and Polymyxin B. Awareness of their entry into a hospital environment is 
the first  step  that  clinical  microbiologists  can  take to  address  this  problem.  Care  in 
detection,  evaluation  of  effective  antibiotic  options,  judicious  use  of  antibiotics  by 
instituting  antibiotic  policy  of  combination  therapy  and  rigorous  infection  control 
measures  will  help  to  fight  against  these  multidrug  resistant  nonfermenters  in  the 
effective management of patients 
APPENDIX
1. oxidase test 57
This test is mainly done to differentiate organisms lacking cytochrome oxidase 
enzyme, mainly the members of enterobactericeae. This enzyme helps in the transfer of 
electrons to oxygen, with formation of water.
The  dye  tetramethyl  paraphenylene  diamine  dihydrochloride  is  substituted  for 
oxygen as artificial  electron acceptor.  In the reduced state,  it  is  colorless  and in the 
presence of cytochrome oxidase and oxygen it forms indophenol, which is purple.
Strips impregnated with dried reagents were used.  The colony was taken on a 
wooden stick and smeared onto the strip. The appearance of purple color within 10 sec. 
was taken as positive.
2. CATALASE TEST 57
Organisms’ possessing the enzyme catalase splits hydrogen peroxide into water 
and oxygen. The evolution of oxygen appears as bubbles.
Tube catalse test was performed 3ml of 3% Hydrogen peroxide was taken in a test 
tube. The colony of the organism to be tested was taken on a glass rod and introduced 
into the tube. Appearance of brisk effervescence was taken as positive.
3. MOTILITY57
Motility  was  done  by  hanging  drop  method.  A drop  of  saline  with  the  test 
organism was  placed  on  the  coverslip.  The  hanging drop slide  is  inverted  over  the 
coverslip where wax had been applied on the corners. The slide is turned quickly so that  
drop is in centre of the concavity. The edge of the drop is focused on the low power and 
high power objectives. Motility was observed.
4. INDOLE TEST57
Indole is a benzyl pyroll  which is a metabolic product of tryptophan. Bacteria 
which possess tryptophanase hydrolyse trytophan to indole.
           The organism was inoculated in peptone water medium, incubated at 37 0C for 18-
24  hours,  1ml  of  zylene  was  added  and  Erlichs’reagent  (Para  dimethyl  amino 
benzaldehyde) was added drop by drop. Formation of fuchsia red ring was positive. It is 
a red complex of indole and paradimethylaminobenzaldehyde.
5. TRIPLE SUGAR IRON MEDIUM 57
Triple sugar iron medium was taken and the organism was stabbed to the butt as 
well streaked on the surface. It was incubated for 18-24hours at 370C, and then looked 
for the presence of growth and change in pH Growth with no change in PH (slant and 
butt) indicated the organism to be nonfermenting. 
6. CITRATE UTILIZATION TEST 57
Sodium citrate is a salt of citric acid seen in metabolism in Krebs cycle. Some 
bacteria utilize citrate as the sole source of carbon and it is detected by the production of 
alkaline byproducts Christensen’s citrate media was used.
The organisms were streaked on the surface of the slant and incubated at 370C for 
18-24hrs. Development of deep blue color of the medium with growth was taken as 
positive.
8. UREASE TEST 57
Urea is a diamide carbonic acid which when hydrolyzed releases ammonia and 
carbon  dioxide.   Urease  is  an  enzyme  when  present  hydrolyses  urea  and  release 
ammonia changing the medium to alkaline, PH.
The organism was streaked on the surface of the slant and incubated at 370C for 
18-24 hours. Development of magenta pink of the medium along with growth was taken 
as positive.
9. NITRATE REDUCTION TEST 57
The capacity of an organism to reduce nitrates to nitrites is shown by this test. The 
presence  of  nitrate  in  the medium is  detected by addition of   α naphthalamine  and 
sulphanilic acid.
          The organism was inoculated in nitrate broth and incubated at 37oC for 18-24 
hours and observed for gas production by Durham’s tube. One ml each of reagents  α 
naphthalamine  &  sulphanilic  acid  were  added  simultaneously  and  looked  for  the 
development of red color.
Development of red color was taken as positive and when it was negative zinc 
dust was added. When the red color developed after adding zinc the test was taken as 
negative because it indicated the presence of residual nitrates.
10. Growth at 420C 57
The organism was plated in nutrient agar plate and incubated at 420C for 18-24 
hours and looked for growth. Presence of uniform growth indicated positive results.
11. Growth at 440C 57
The organism was plated in nutrient agar plate and incubated at 440C for 18-24 
hours and looked for growth. Presence of uniform growth indicated positive results.
12. Polymyxin B Sensitivity 57
The organism was plated on nutrient agar plate and a polymyxin B disc of 300U 
was kept. It was incubated at 37oc for 18-24 hrs and looked for zone of inhibition
SPECIAL BIOCHEMICAL TESTS USED FOR IDENTIFICATION OF NON 
FERMENTERS 
1. HUGH – LEIFSON OXIDATION - FERMENTATION MEDIUM57
Peptone : 2g
Sodium Chloride : 5g
D-Glucose : 10g
Bromothymol blue : 0.03g
Agar : 3.0g
Dipotassium Phosphate : 0.3g
Distilled water : 1 litre
pH : 7%
Medium was sterilized by autoclaving. After cooling the medium to 450C, filter 
sterilized  carbohydrate  solution  was  added  to  get  a  final  concentration  of  1% 
Carbohydrates used for the study were glucose, maltose, xylose, fructose and mannitol. 
Of medium was poured as a butt and without a slant into tubes. Two tubes were required 
for the test, each inoculated with the unknown organism, using a straight needle stabbing 
the medium three to four times half way to the bottom of the tube. One tube of each pair  
was covered with a 1cm layer of sterile mineral oil (or) melted paraffin, leaving the 
other open to the air. Both tubes were incubated at 350C and examined daily for several 
days.
In case of oxidative metabolism, yellow color appears along the upper one fourth 
of the medium and in the tube where no oil overlay was done. In case of fermentative 
organisms yellow color develops in both the tubes.
CONTROL
Glucose fermentation : Escherichia coli
Glucose oxidation : Pseudomonas aeruginosa
Non saccharolytic: Alcaligenes species.
2. DECARBOXYLATION OF LYSINE, ARGININE & ORNITHINE 57
Decarboxylases are a group of specific enzymes which react with carboxyl portion 
of aminoacid forming alkaline reacting amines. The reaction is decarboxylation.  Each 
enzyme is specific for Lysine, Arginine and Ornithine.
INGREDIENTS
Yeast extract : 5g
Peptone : 5g
Glucose : 0.5g
Pyridoxal : 5mg
Bromocresol Purple : 5ml
Cresol Red : 2.5ml
Distilled water : 1 ltr.
All  aminoacids  were  added  individually  to  a  final  concentration  of  1%  pH 
adjusted at 6.0 & autoclaved at 15lbs for 15 minutes.
PROCEDURE
   The organism was inoculated in four tubes. One having the basal medium without 
aminoacid for control. Other three tubes having lysine, arginine and ornithine each. All 
tubes were overlaid with liquid paraffin. All were incubated at 370C for 24 hours.
The control tube turned yellow indicating that the organism is viable and the test 
medium turning blue purple indicating positive result.
3. O–NITROPHENYL β - D GALACTOPYRANOSIDE 57
Reagent 
Sodium Phosphate buffer 1M pH 7.0 – 5ml
O – Nitrophenyl β  - D – galactopyranoside – 80mg
Distilled water – 15ml.
A dense suspension of the test organism grown in TSI agar was prepared in saline. 
About 1 drop of toluene was added to the suspension and 0.2ml of ONPG solution was 
added to the suspension and incubated at 370C     β-galactosidase producing organism 
show yellow color after 1 hour or 18-24 hours incubation.
CONTROL
Positive Control – Escherichia coli
Negative control – Proteus species.
4. ACETAMIDE AGAR 11
Ingredients
Magnesium Sulphate : 0.2g
Ammonium dihydrogen Phosphate : 1g
Pottasium monohydrogen phosphate : 1g
Sodium Chloride : 5g
Acetamide : 10g
Bromothymol blue solution : 6.4ml
Agar : 15g
Final pH : 6.9
Distilled water : 1 litre
The ingredients are mixed and pH adjusted to 6.9, dispensed into screw cap tubes 
and sterilized at 1210C for 15 min. The medium was allowed to cool in a slant. The slant 
was inoculated with a portion of isolated colony and incubated at 370C overnight and 
was observed for color change. Tubes with negative result were further incubated for 7 
days. 
Control
Positive control : Pseudomonas aeruginosa
Negative Control : Stenotrophomonas maltophilia
5. GELATIN LIQUEFACTION TEST 57
Gelatin breakdown can be demonstrated by incorporating it in a buffered nutrient 
agar,  growing the culture and then flooding the medium with mercuric chloride that 
differentially precipitates either gelatin or its breakdown products causing opacity in the 
medium with clear zones around gelatin-liquefying colonies 
CONTROL
Positive control : Pseudomonas aeruginosa
Negative Control : Stenotrophomonas maltophilia
PCR Primers and procedure 69
Two sets of primers were used for multiplex PCR. The primers used are given 
below 
IMP   FORWARD – 5’ CTA CCG CCG CAG CAG AGT CTT TG -3’
          REVERSE      5’-AAC CAG TTT TGC CTT ACC AT-3’
VIM   FORWARD    5’- AGT GGT GAG TAT CCG ACA G -3’
          REVERSE      5’-ATG AAA GTG CGT GGA GAC -3
PCR  was  conducted  with  1µl  of  boiled  bacterial  suspensions,  0.5µl  of  each 
primer, 2µl 5mM of dNTP, 2.µl 10mM Tris-HCL (pH 8.3), 0.75 µl 50mM Mgcl2  and 2U 
of Taq DNA polymerase in a total volume of 20µl.
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PROFORMA
Name:                                  I.P:No:                                                   
Department:
Age:                                      Sex:                                                      
Occupation:
Present Complaints and duration:
Present History:
Past History:
Personal History:
Family History:
Clinical Findings:
Investigations:
Management:
Follow-up:
ABBREVIATIONS
NFGNB - Nonfermenting gram negative bacilli
Ps.aeruginosa - Pseudomonas aeruginosa
A.baumanii - Acinetobacter baumanii
Ps.fluorescens - Pseudomonas fluorescens
S.maltophilia - Stenotrophomonas maltophilia
B.cepacia - Burkholderia cepacia
Mac plate - MacConkey plate
MDR - Multidrug resistant
ESBL - Extended Spectrum Of Betalactamases
MBL - Metallobetalactamases
ONPG - O–Nitrophenyl β - D Galactopyranoside

